Fundraising FoxArtielle Immunotherapeutics
Portland, US · 1 known investors
Find your way into Artielle Immunotherapeutics
Sign up to see every warm intro you have to Artielle Immunotherapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Artielle Immunotherapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Artielle Immunotherapeutics develops DRhQ, a therapeutic platform that targets the CD74 receptor and inhibits macrophage migration inhibitory factor (MIF) to treat neuroinflammatory conditions such as progressive multiple sclerosis and advanced cancers. The company builds on research from OHSU and the VA Portland Healthcare System.
Founders & leadership
RS
Renee ShirleyFounder
Investors · 1
Related companies · 6
LyellLyell develops CAR T-cell therapies for cancer patients by leveraging deep expertise in T-cell biology and oncology. The company operates an integrated pipeline spanning discovery through manufacturing and clinical trials, with its own manufacturing facility in Washington.
Oricell TherapeuticsOricell Therapeutics (原启生物) is a clinical-stage biopharmaceutical company developing cell therapies, including CAR-T products targeting GPRC5D for relapsed/refractory multiple myeloma and GPC3 for advanced liver cancer. Based in Shanghai, it builds proprietary antibody and CAR platforms (OriAb, OriCAR) to create cancer immunotherapies for unmet oncology needs such as liver, gastric, pancreatic, biliary, and ovarian cancers.
LinkcelltxLink Cell Therapies is a biotechnology company developing logic-gate LINK CAR-T cell therapies aimed at treating solid and liquid tumors. It works in the cancer immunotherapy space and has a strategic collaboration with Johnson & Johnson.
ImmuneelImmuneel Therapeutics develops and manufactures cell-based immunotherapies, including CAR-T therapies, for cancer patients, with in-house cGMP lentiviral vector manufacturing. The company aims to make next-generation cell therapies affordable and accessible in India, with a global outlook.
GlobaldataGlobalData provides an AI-powered intelligence platform that delivers research, market analysis, and predictive insights to enterprises across industries. The platform combines proprietary data, in-house subject matter experts, and AI tools to support critical business decisions.
RobinhoodRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
Companies working in the same space as Artielle Immunotherapeutics.
Frequently asked questions
- What does Artielle Immunotherapeutics do?
- Artielle Immunotherapeutics develops DRhQ, a therapeutic platform that targets the CD74 receptor and inhibits macrophage migration inhibitory factor (MIF) to treat neuroinflammatory conditions such as progressive multiple sclerosis and advanced cancers. The company builds on research from OHSU and the VA Portland Healthcare System.
- Who founded Artielle Immunotherapeutics?
- Artielle Immunotherapeutics was founded by Renee Shirley.
- Who are Artielle Immunotherapeutics's investors?
- Artielle Immunotherapeutics's investors include Sanderling Ventures.
- Where is Artielle Immunotherapeutics headquartered?
- Artielle Immunotherapeutics is headquartered in Portland, US.